MA-ROSLINCT
25.6.2024 09:01:32 CEST | Business Wire | Press release
RoslinCT, a leading cell and gene therapy Contract Development and Manufacturing Organisation (CDMO), is pleased to announce the appointment of Professor Sir Peter Mathieson MB BS (Hons), PhD, FRCP, FRCPE, FMedSci, FRSE, FRSA and Alexander Vos as new Non-Executive Directors.
Professor Sir Peter Mathieson brings an exceptional wealth of experience in higher education, medical research, and organisational leadership. Currently serving as the Principal of the University of Edinburgh since 2018, Sir Peter also holds Honorary Professorships in Medicine at the Universities of Edinburgh, Hong Kong, and Bristol. His illustrious career includes notable roles such as President of the University of Hong Kong (2014-18) and Dean of the Faculty of Medicine & Dentistry at the University of Bristol (2008-14). Sir Peter was knighted in the 2023 New Year Honours for his services to higher education, reflecting his significant contributions to the field. Additionally, Sir Peter has held numerous non-executive and trustee roles, including positions with the Renal Association, Council for the Advancement and Support of Education (CASE), Scottish Funding Council, and Newbattle Abbey College Trust. His career highlights also include tenure as an honorary consultant nephrologist with a clinical interest in autoimmune diseases and renal transplantation. He has led a significant research group in Bristol and contributed extensively to medical education and clinical research, particularly in Africa. His publication record includes 327 works, covering clinical trials, laboratory research, and societal matters, and he has been a driving force in academic careers both in the UK and internationally.
Alexander Vos is a biotech leader with 30 years of experience, specializing in biopharmaceuticals and cell & gene therapy. He started at McKinsey & Co. and held executive roles at Genzyme Therapeutics Europe. He was CEO of MediService AG, PAION AG's Deputy-CEO and COO, and led PharmaCell BV to a successful sale to Lonza. Vos also served as CEO of VarmX and VectorY, setting strategy and raising significant funds for these companies. Currently, he sits on several biotech boards and is a Venture Partner at BioGeneration Ventures. He holds an MS in Pharmacy and Pharmacology and an MBA from Stanford University. Alexander Vos's proven leadership in advancing innovative therapies and achieving successful exits for investors will be invaluable to RoslinCT. His skills in biotech strategy development, operations, and M&A will complement the existing strengths of the board.
"We are excited to welcome both Professor Sir Peter Mathieson and Alexander Vos to our Board," said Geoffrey Hamilton Fairley, Executive Chairman of the RoslinCT Group. "Sir Peter's extensive experience in academic leadership and his proven track record in advancing medical research and education, combined with Alexander's strategic insight and wealth of experience in biotech and cell and gene therapy, align perfectly with RoslinCT's mission. Their combined expertise will be instrumental as we continue to develop and manufacture cutting-edge cell and gene therapies."
"I am honoured to join RoslinCT at such an exciting time for the company and the field of cell and gene therapy," said Sir Peter Mathieson. "I look forward to contributing to RoslinCT's innovative efforts to bring life-saving therapies to patients worldwide."
Alexander Vos added, "I am excited to be part of RoslinCT's journey and to support its mission to advance cell and gene therapies. The company is at the forefront of groundbreaking science, and I am eager to contribute to its continued success."
About RoslinCT
RoslinCT is a leading global contract development and manufacturing services organization (CDMO) focused on Advanced Cell and Gene Therapies. Established in 2006 and built upon the ground-breaking technology cloning of Dolly the Sheep at the Roslin Institute in 1997, RoslinCT has harnessed cutting-edge science to advance the development of human medicines. With a remarkable heritage in the field, the company has achieved significant milestones. These include being among one of the first in the world to produce clinical-grade human pluripotent stem cells. In collaboration with the partners, RoslinCT also developed the first CRISPR-edited cell therapy product for a major inherited disorder, taking it from early development to commercialisation.
Equipped with 22 purpose-built cGMP cell therapy processing suites in Edinburgh, Scotland, and Hopkinton, Massachusetts, RoslinCT provides innovative process and analytical development, cGMP clinical and commercial manufacturing for a range of cell types for both autologous and allogeneic processes, and cGMP iPSC cell line development, gene editing, and differentiation.
With tailored CDMO solutions, RoslinCT enables partners to efficiently progress from development to commercialisation and deliver life-saving Cell and Gene Therapies worldwide. RoslinCT is a GHO Capital portfolio company. Discover more about our services at www.roslinct.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240625300790/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TestMu AI (Formerly LambdaTest) Recognized in Independent Research on Autonomous Testing Platforms, Q4 20252.2.2026 18:24:00 CET | Press release
Research cites AI testing, data generation, and accelerated execution TestMu AI (formerly known as LambdaTest), the world’s first full-stack Agentic Quality Engineering platform, today announced its inclusion in The Forrester Wave™: Autonomous Testing Platforms, Q4 2025, an independent research report evaluating vendors in the autonomous testing market. The report identifies TestMu AI as a cloud-based platform for unified test orchestration and execution. It notes the platform's capabilities in cross-browser testing, real device cloud, and AI-driven automation. Specifically, the research cites TestMu AI’s testing of AI systems across dimensions, providing metrics for accuracy, intent recognition, and hallucination detection with configurable thresholds. Additionally, the report recognizes TestMu AI’s AI-powered test data generation, citing its support for Large Language Models (LLMs), multimodal inputs, and compliance-aligned workflows. The report also noted the company's strong commun
Current Chemicals Launches as Independent Specialty Materials Manufacturer, Building on 75-Year GE Legacy with Backing from Momentum Global Ventures2.2.2026 17:04:00 CET | Press release
Today marks the debut of Current Chemicals, Inc. (CCI) as a fully independent U.S.-based specialty materials manufacturer. Backed by strategic investor Momentum Global Ventures, CCI is charting a bold new path as a trusted partner for materials innovation, custom chemistry, and U.S.-based downstream manufacturing of rare earths and critical materials. The partnership between U.S.-based CCI and Netherlands-based Momentum Global Ventures reflects a strengthening transatlantic alliance at a pivotal moment for global supply chains. This partnership underscores a shared commitment to secure, reliable, and innovation-driven materials infrastructure. Originally the chemical division of GE Lighting, the team behind CCI has served as the quiet force behind groundbreaking technologies for more than 75 years, developing processes and manufacturing advanced materials for displays, lighting, energy storage, and more. As an independent company, CCI is poised to expand its impact across industries de
Laserfiche’s Taylor Grosso Honored as 2026 CRN® Channel Chief2.2.2026 16:00:00 CET | Press release
Laserfiche — the leading SaaS provider of intelligent content management — announced today that CRN® — a brand of The Channel Company — has selected Taylor Grosso, senior director, channel, Americas, as a 2026 CRN® Channel Chief. This annual recognition celebrates IT vendor and distribution executives who are shaping channel strategy and driving innovation and partnership across the industry. Grosso oversees Laserfiche’s Americas channel sales team, including the U.S., Canada, and Latin America, focusing on empowering Laserfiche Solution Providers to stay competitive as the market evolves. As more organizations seek out AI-powered tools to enhance productivity, Grosso prepares partners with the resources they need to quickly learn and sell Laserfiche’s industry-leading AI-powered document management solutions. By working closely with partners on building targeted business plans, Grosso and his team enable faster customer adoption of AI while driving revenue growth. “Over the past year,
Conga Completes Acquisition of PROS B2B Business2.2.2026 15:55:00 CET | Press release
Redefines Commercial Excellence for Enterprises with a Clear Path from Price to Signature Conga, a leader for AI-powered innovation in configure, price, quote (CPQ), contract lifecycle management (CLM), and document automation, today announced it has completed the acquisition of the B2B business of PROS Holdings, Inc (“PROS”) from certain investment funds affiliated with Thoma Bravo, the world’s largest software-focused investment firm. This transaction unites two industry leaders to help enterprises maximize revenue, reduce risk, and improve profitability. By bringing together AI-driven pricing optimization, configuration, quoting, and contracting capabilities, the combined company creates a differentiated enterprise platform that connects the commerce chain and enables end-to-end revenue orchestration from price to signature. The expanded Conga leadership team will continue to be led by CEO Dave Osborne. “To operate as connected, intelligent businesses, enterprises need a commerce ch
Andersen Consulting styrker sit udbud inden for digital transformation gennem samarbejde med iNNOVATEQ2.2.2026 15:38:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med iNNOVATEQ, der er et Muscat-baseret digitalt transformationsfirma, der redefinerer det digitale oliefelt gennem indsigter i realtid, intelligente arbejdsgange, driftsmæssig ekspertise og produktionsoptimering på tværs af olie- og gasværdikæden. iNNOVATEQ blev grundlagt i 2018 og udsprang fra Petroleum Development of Omans (PDO) digitale transformationsprogram og trækker på en stærk operatør-DNA samt praktisk erfaring fra samarbejde med nogle af verdens største nationale og internationale olieselskaber. Virksomheden specialiserer sig i bæredygtig forretningstransformation gennem praktiske, formålstilpassede digitale løsninger leveret via deres Nibras-platform; et system til aktiv- og produktionsstyring. Med et team på mere end 100 specialister og en voksende international kundebase understøtter iNNOVATEQ sine kunder ved at kombinere digitale initiativer, effektivisering af driften og skalering af intellektuel ejendom til pålidelige
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom